What it's for (Indications)
- Cholecalciferol, also known as Vitamin D3, is primarily indicated for the prevention and treatment of vitamin D deficiency and its associated conditions.
- This includes the management of rickets and osteomalacia in both pediatric and adult populations, where inadequate vitamin D levels lead to defective bone mineralization.
- It serves as crucial adjunctive therapy in the prevention and treatment of osteoporosis, often prescribed in conjunction with calcium to support bone health and reduce fracture risk.
- Furthermore, cholecalciferol is utilized in patients with conditions predisposing to vitamin D insufficiency, such as malabsorption syndromes (e.
- g.
- , celiac disease, Crohn's disease, cystic fibrosis, post-bariatric surgery states), chronic kidney disease, and hypoparathyroidism, where calcium homeostasis is compromised.
- Its role extends to supporting overall musculoskeletal health and numerous non-skeletal functions, including immune system modulation and cell proliferation regulation.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cholecalciferol is highly individualized, varying significantly based on the patient's age, baseline vitamin D status (serum 25-hydroxyvitamin D levels), underlying medical conditions, and therapeutic goals. For the treatment of established vitamin D deficiency, higher initial loading doses are often prescribed, such as 50,000 International Units (IU) orally once weekly for 8 to 12 weeks, or equivalent cumulative doses administered less frequently (e.g., a single high-dose ampoule like Miura-D Ampoule for intramuscular or oral use). Maintenance therapy typically involves lower daily or weekly doses, ranging from 800 IU to 2000 IU per day, to sustain adequate serum levels. In specific populations like infants, children, or pregnant women, dosage guidelines differ and must be followed meticulously. Regular monitoring of serum 25(OH)D, calcium, and phosphorus levels is imperative, particularly during high-dose therapy, to ensure efficacy and prevent toxicity. Adjustments to dosage should always be made under the guidance of a healthcare professional based on clinical response and laboratory parameters. |
Safety & Warnings
Common Side Effects
- Cholecalciferol is generally well-tolerated when administered within recommended therapeutic ranges.
- However, adverse effects predominantly occur due to excessive intake, leading to vitamin D toxicity (hypervitaminosis D), which manifests primarily through hypercalcemia.
- Symptoms of hypercalcemia can include non-specific complaints such as nausea, vomiting, anorexia, constipation, dry mouth, and a metallic taste.
- More severe manifestations involve polyuria, polydipsia, fatigue, headache, dizziness, muscle weakness, and bone pain.
- Prolonged or severe hypercalcemia can result in serious complications, including nephrocalcinosis, nephrolithiasis (kidney stone formation), renal impairment, cardiac arrhythmias, and hypertension.
- In very rare and extreme cases, hypervitaminosis D can lead to coma and death.
- Allergic reactions, though uncommon, may occur, presenting as rash, itching, or swelling.
- Prompt medical attention is warranted if any signs of toxicity or severe allergic reactions develop, and the medication should be discontinued immediately.
Serious Warnings
- Black Box Warning: Cholecalciferol, as an active pharmaceutical ingredient, does not have an FDA-mandated Black Box Warning. A Black Box Warning is reserved for medications that carry significant risks of serious or life-threatening adverse effects that may be mitigated by careful monitoring or specific patient selection. However, clinicians and patients should be acutely aware of the potential for serious adverse effects, particularly **hypercalcemia** and **hypervitaminosis D**, if cholecalciferol is administered in excessive doses or without appropriate monitoring of serum calcium, phosphorus, and 25-hydroxyvitamin D levels. For comprehensive details regarding these critical safety considerations and other warnings, please refer to the "Warnings" section provided in this document, which outlines the significant risks and necessary precautions for safe cholecalciferol usage. Prudent medical practice dictates careful dose titration and regular laboratory surveillance to prevent these potentially severe outcomes, which can include renal impairment and cardiac abnormalities.
- **Serious Warnings:** While cholecalciferol does not carry a formal FDA Black Box Warning, it is crucial for healthcare providers and patients to be aware of several serious risks associated with its use, particularly at high doses.
- The most significant concern is the potential for **hypercalcemia** and subsequent **hypervitaminosis D**.
- Over-supplementation can lead to dangerously elevated serum calcium levels, resulting in symptoms such as nausea, vomiting, polyuria, cardiac arrhythmias, and potentially irreversible renal damage (nephrocalcinosis, nephrolithiasis).
- Close monitoring of serum calcium, phosphorus, and 25-hydroxyvitamin D levels is therefore essential, especially in patients receiving high-dose therapy, those with impaired renal function, or individuals predisposed to hypercalcemia.
- Patients with granulomatous diseases like sarcoidosis exhibit increased sensitivity to vitamin D and are at a higher risk of hypercalcemia due to enhanced extra-renal conversion of calcifediol to calcitriol.
- Caution is also advised in patients with a history of kidney stones or those undergoing dialysis, as vitamin D can exacerbate these conditions.
- Drug interactions, notably with thiazide diuretics (increasing hypercalcemia risk), anticonvulsants (decreasing vitamin D efficacy), and bile acid sequestrants (impairing absorption), must be carefully considered to prevent adverse outcomes and ensure therapeutic efficacy.
- Pediatric and pregnant patients require specific dosing considerations and careful monitoring.
How it Works (Mechanism of Action)
Cholecalciferol (Vitamin D3) functions as a prohormone, requiring metabolic activation to exert its physiological effects. Upon ingestion or synthesis in the skin via ultraviolet B (UVB) radiation, cholecalciferol undergoes its initial hydroxylation in the liver by 25-hydroxylase enzymes (e.g., CYP2R1, CYP27A1) to form 25-hydroxyvitamin D [25(OH)D], also known as calcifediol. This calcifediol is the primary circulating form of vitamin D and serves as the best indicator of the body's vitamin D stores. The second, rate-limiting hydroxylation step occurs predominantly in the kidneys, where 25(OH)D is converted to the biologically active form, 1,25-dihydroxyvitamin D [1,25(OH)2D], or calcitriol, by the enzyme 1-alpha-hydroxylase (CYP27B1), a process tightly regulated by parathyroid hormone (PTH) and phosphate levels. Calcitriol acts as a potent steroid hormone, binding to the intracellular vitamin D receptor (VDR) present in target cells throughout the body. Activation of VDRs leads to gene transcription, primarily regulating calcium and phosphate homeostasis. This involves increasing the efficiency of intestinal absorption of dietary calcium and phosphate, modulating renal reabsorption of these minerals, and influencing bone mineralization and remodeling. Calcitriol also plays significant roles in immune modulation, cell growth, and differentiation, underscoring its broad physiological importance beyond mineral metabolism.